Das lnverkehrbringen von Arzneimitteln mit neuen Wirkstoffen ist in der Bundesrepublik Deutschland mit besonderen Auflagen f\u00fcr einen Zeitraum von mindestens f\u00fcnf Jahren – abgesehen von wenigen begr\u00fcndeten Ausnahmen – nach erstmaliger Zulassung verbunden. Diese Arzneimittel unterliegen einer f\u00fcnfj\u00e4hrigen automatischen Verschreibungspflicht. Nach der erstmaligen Zulassung sind dem Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM) vom pharmazeutischen Unternehmer […]<\/p>\n","protected":false},"excerpt":{"rendered":"
Das lnverkehrbringen von Arzneimitteln mit neuen Wirkstoffen ist in der Bundesrepublik Deutschland mit besonderen Auflagen f\u00fcr einen Zeitraum von mindestens f\u00fcnf Jahren – abgesehen von wenigen begr\u00fcndeten Ausnahmen – nach erstmaliger Zulassung verbunden. Diese Arzneimittel unterliegen einer f\u00fcnfj\u00e4hrigen automatischen Verschreibungspflicht. Nach der erstmaligen Zulassung sind dem Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM) vom pharmazeutischen Unternehmer […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1742,1743,330,130,1751,1746,316,309,312,314,313,315,389,255,317,320,311,307,319,310,821,472,1745,1226,1741,1609,451,1747,449,1749,1744,1069,1636,1750,1748,1637,1755,1760,687,455,1772,1762,453,49,1769,1767,1765,1228,763,1753,1771,1042,1752,456,1757,1761,257,1770,561,1768,558,1766,401,1773,1672,1758,1763,1764,1756,1754,1759,1735,306,1738,1740,443,1431,1737,1739,1736],"class_list":["post-695","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-s-ketamin","tag-13c-harnstoff","tag-5-hydroxytryptamin-rezeptor-antagonisten","tag-ace-hemmer","tag-aceclofenac","tag-adenosin","tag-angiotensin-ii-antagonisten","tag-angiotensin-ii-blocker","tag-angiotensin-ii-inhibitoren","tag-angiotensin-ii-rezeptor-antagonisten","tag-angiotensin-ii-rezeptor-blocker","tag-angiotensin-ii-rezeptor-inhibitoren","tag-aromatasehemmer","tag-arzneimittel","tag-at-ii-antagonisten","tag-at-ii-blocker","tag-at-ii-inhibitoren","tag-at-ii-rezeptor-antagonisten","tag-at-ii-rezeptor-blocker","tag-at-ii-rezeptor-inhibitoren","tag-atovaquon-proguanil","tag-budesonid","tag-budipin","tag-candesartan","tag-cefpirom","tag-cerivastatin","tag-cholesterinsynthese-hemmer","tag-cidofovir","tag-cse-hemmer","tag-desirudin","tag-dolasetron","tag-donepezil","tag-eprosartan","tag-fexofenadin","tag-formoterol","tag-fosinopril","tag-grepafloxacin","tag-harnstoff-13c","tag-hirudin","tag-hmg-coa-reduktase-hemmer","tag-hydrochlorothiazid-losartan","tag-hydrochlorothiazid-valsartan","tag-hypercholesterinaemie","tag-insulin-lispro","tag-interferon-beta-1a","tag-iosarcol","tag-ipratropium","tag-irbesartan","tag-ketamin","tag-latanoprost","tag-lepirudin","tag-letrozol","tag-levacetylmethadol","tag-lipidsenker","tag-losartan-hydrochlorothiazid","tag-mangafodipir","tag-medikamente","tag-mercaptamin","tag-mibefradil","tag-miglitol","tag-migraene","tag-mizolastin","tag-nadroparin","tag-naratriptan","tag-nefazodon","tag-papaverin-phentolamin","tag-phentolamin-papaverin","tag-pilocarpin","tag-porfimer","tag-pramipexol","tag-proguanil-atovaquon","tag-reboxetin","tag-sartane","tag-sertindol","tag-spaglumin","tag-statine","tag-tolcapon","tag-triptane","tag-valsartan-hydrochlorothiazid","tag-zolmitriptan"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/695","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=695"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/695\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=695"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=695"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=695"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}